SCHEMBL8065207

SCHEMBL8065207

Cc1nc(N)ncc1-c1nc(N2CCOCC2)nc2c1ncn2C(C)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 11/20 0.59
MTOR P42345 5/20 0.59
PIK3R1 P27986 4/20 0.53
ADORA2A P29274 1/20 0.47
PIK3CD O00329 5/20 0.46
PIK3CB P42338 2/20 0.46
PIK3CG P48736 2/20 0.46
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
JAK3 P52333 1/20 0.46
HDAC3 O15379 7/20 0.43
HDAC4 P56524 7/20 0.43
HDAC1 Q13547 7/20 0.43
HDAC7 Q8WUI4 7/20 0.43
HDAC2 Q92769 7/20 0.43
HDAC10 Q969S8 7/20 0.43
HDAC11 Q96DB2 7/20 0.43
HDAC8 Q9BY41 7/20 0.43
HDAC6 Q9UBN7 7/20 0.43
HDAC9 Q9UKV0 7/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8050265 0.91 PIK3CA (0.51) PIK3CAMTORPIK3R1ADORA2APIK3CD
SCHEMBL8053186 0.88 PIK3CA (0.76) PIK3CAMTORPIK3R1ADORA2APIK3CD
SCHEMBL8067087 0.84 PIK3CA (0.62) PIK3CAMTORPIK3R1PIK3CDPIK3CB
SCHEMBL8053699 0.84 PIK3CA (0.61) PIK3CAMTORPIK3R1PIK3CDPIK3CB
SCHEMBL8050492 0.83 PIK3CA (0.62) PIK3CAMTORPIK3R1ADORA2APIK3CD
SCHEMBL8062411 0.82 PIK3CA (0.59) PIK3CAMTORPIK3R1PIK3CDPIK3CB
SCHEMBL12945852 0.77 PIK3CA (0.52) PIK3CAMTORPIK3R1PIK3CDPIK3CB
SCHEMBL1569338 0.77 PIK3CA (0.55) PIK3CAMTORPIK3R1PIK3CDPIK3CB
SCHEMBL12910221 0.76 PIK3CA (0.56) PIK3CAMTORHDAC3HDAC4HDAC1
SCHEMBL1568801 0.76 PIK3CA (0.57) PIK3CAMTORPIK3R1PIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140066620-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES VERASTEM, INC. (US) 2014-03-06 US disclosed
US-20140066620-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES VERASTEM, INC. (US) 2014-03-06 US disclosed
US-20130079512-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES Verastem (US) 2013-03-28 US disclosed
US-20130079512-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES Verastem (US) 2013-03-28 US disclosed
EP-2209786-B1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES VERASTEM INC (US) 2013-02-27 EP disclosed
US-8247410-B2 Pyrimidine substituted purine derivatives Verastem (US) 2012-08-21 US disclosed
US-8247410-B2 Pyrimidine substituted purine derivatives Verastem (US) 2012-08-21 US disclosed
US-20100298319-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES S*BIO PTE LTD. (SG) 2010-11-25 US disclosed
US-20100298319-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES S*BIO PTE LTD. (SG) 2010-11-25 US disclosed
WO-2009045175-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES S*BIO PTE LTD (SG) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066620-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES TYMP, PIK3CA, PNP PIK3CA 2/4885MTOR 7/4885PIK3R1 153/4885
US-20100298319-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES TYMP, PIK3CA, PNP PIK3CA 2/4885MTOR 7/4885PIK3R1 153/4885
US-20130079512-A1 PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES TYMP, PIK3CA, PNP PIK3CA 2/4885MTOR 7/4885PIK3R1 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.